Polycythemia vera is not hereditary. While it results from a genetic mutation, or a change in the DNA in a bone marrow cell, the change usually develops during life.

Tailoring medicines to an individual’s genetic profile is now possible. One critical aspect is genetic testing that reduces side effects, particularly for patients on psychiatric and cardiovascular ...

Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of hereditary angioedema (HAE) attacks in patients 12 years and older.

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the inflammatory cascade that drives attacks.

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) approved ANDEMBRY® (garadacimab-gxii), the only treatment targeting factor XIIa ...

"We are thrilled to share positive initial results from the ALPHA-SOLAR long-term open-label trial," said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics.

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and ...

Bankrupt 23andMe is facing a lawsuit over its plans to sell customer genetic information. Twenty-seven states and the District of Columbia took legal action this week against 23andMe in the U.S ...

Twenty-seven states and the District of Columbia have sued the bankrupt genetic testing company 23andMe in an effort to block the company's sale of its customers' genetic data.

Over the weekend, biotechnology company 23andMe filed for Chapter 11 bankruptcy. Questions remain over what could happen to users' genetic data?

Genetic study reveals hidden chapter in human evolution Date: March 18, 2025 Source: University of Cambridge Summary: Modern humans descended from not one, but at least two ancestral populations ...